Apple Tree Partners (ATP) is a venture capital firm specializing in startup, early venture, and growth capital investments. ATP seeks to invest in proprietary products and technologies within the life sciences, IT and biotech sectors, with a focus on drug development, therapeutics and drug discovery, among others.
Excel Venture Management builds companies that apply transformative life science technologies to solve problems in healthcare with an investment portfolio spanning healthcare IT and services, diagnostics, medical devices and life sciences. The majority of the team’s prior investments, which include some of the world’s premier healthcare and life science companies, are thriving and over half have achieved successful exits generating billions in value.
Lilly Ventures has its roots in the scientific tradition of Eli Lilly and Company, with a philosophy that drives its investment in great companies with compelling life science innovations. Lilly Ventures partners actively with the management teams of its portfolio companies to realize the potential of their technologies and provides both financial and intellectual resources to accelerate the management teams’ path to success. Lilly Ventures currently has $200 million under management with a focus on the North American and European regions.
Novartis Venture Fund’s (NVF) mission is to build a diverse portfolio of life science companies across the biotech, medical devices and diagnostics industries. The fund invests in innovation that is strategic to the entire healthcare industry. NVF looks for companies in the USA, Europe, Israel and Asia-Pacific that it believes have the potential to offer significant patient benefit. Together with the commitment of other syndicate investors, more than $2.5 billion is currently invested into NVF portfolio companies.
Roche Venture Fund invests in early stage biotech and diagnostics companies to develop commercially successful innovative life science companies. Based in Basel, Switzerland with an office in South San Francisco, the Roche Venture Fund invests globally with a portfolio of 34 companies in 10 countries.
SR One is the independent corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested in more than 170 companies and has a current portfolio of approximately 40 private and public companies.